[ad_1]
When not busy making an attempt to resurrect the wooly mammoth, geneticist George Church spends his time launching new biotech firms at a tempo practically on par with SpaceX sending rockets into house. Finally depend, he had co-founded or in any other case helped kickstart about 50 completely different firms – lots of which have gained some quantity of traction. For example, Ginkgo Bioworks (DNA) acquired one among his very first ventures, an artificial biology startup referred to as Gen9 that we coated on the time. Actually, we’ve written about a lot of the Harvard professor’s many companies, and even held shares in one other early enterprise, Editas Drugs (EDIT), earlier than exiting our place in 2022.
One other one among Church’s earliest startups was an organization referred to as ReadCoor whose intellectual property (IP) would finally grow to be a key expertise that’s presently serving to gasoline development for 10X Genomics (TXG). The biotech firm not too long ago launched its 2023 year-end outcomes. Income climbed 20% year-over-year to greater than $618 million after development hit a wall the prior yr in 2022. New product platforms are serving to revive development, although the corporate’s flagship platform remains to be flagging and gross margins are nonetheless shrinking. Let
[ad_2]
Source link
